XBiotech Inc (XBIT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
XBiotech Inc stock (XBIT) is currently trading at $2.36. XBiotech Inc PS ratio (Price-to-Sales) is 12.23. Analyst consensus price target for XBIT is $18.00. WallStSmart rates XBIT as Sell.
- XBIT PE ratio analysis and historical PE chart
- XBIT PS ratio (Price-to-Sales) history and trend
- XBIT intrinsic value — DCF, Graham Number, EPV models
- XBIT stock price prediction 2025 2026 2027 2028 2029 2030
- XBIT fair value vs current price
- XBIT insider transactions and insider buying
- Is XBIT undervalued or overvalued?
- XBiotech Inc financial analysis — revenue, earnings, cash flow
- XBIT Piotroski F-Score and Altman Z-Score
- XBIT analyst price target and Smart Rating
XBiotech Inc
📊 No data available
Try selecting a different time range
Smart Analysis
XBiotech Inc (XBIT) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
XBiotech Inc (XBIT) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
XBiotech Inc (XBIT) Areas to Watch (5)
Company is destroying shareholder value
Revenue declining -93.30%, a shrinking business
Very expensive at 12.2x annual revenue
Very low institutional interest at 7.69%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
XBiotech Inc (XBIT) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.52) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (12.23) suggest expensive pricing. Growth concerns include Revenue Growth at -93.30%, which may limit upside. Profitability pressure is visible in Return on Equity at -28.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -28.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -93.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
XBIT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
XBIT's Price-to-Sales ratio of 12.23x trades at a deep discount to its historical average of 162.35x (21th percentile). The current valuation is 99% below its historical high of 826.22x set in Mar 2024, and 132% above its historical low of 5.27x in Nov 2022. Over the past 12 months, the PS ratio has compressed from ~315.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for XBiotech Inc (XBIT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
XBiotech Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 300,000 with 93% decline year-over-year.
Key Findings
Spending 8453% of revenue (25M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 93% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -23M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact XBiotech Inc.
Bottom Line
XBiotech Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About XBiotech Inc(XBIT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases. The company is headquartered in Austin, Texas.